当前位置: X-MOL 学术J. Exp. Clin. Cancer Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Correction to: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Journal of Experimental & Clinical Cancer Research ( IF 11.3 ) Pub Date : 2020-01-13 , DOI: 10.1186/s13046-019-1518-z
Ssu-Chuan Lai , Yu-Ting Su , Ching-Chi Chi , Yung-Che Kuo , Kam-Fai Lee , Yu-Chih Wu , Pei-Chi Lan , Muh-Hwa Yang , Te-Sheng Chang , Yen-Hua Huang

In the original publication of this article [1], labelling within Fig. 7a was incorrect. The updated figure is shown below, with 'DMT1' now corrected to read 'DNMT1'.

中文翻译:

纠正:DNMT3b / OCT4表达通过IL-6 / STAT3调节赋予索拉非尼耐药性和肝细胞癌预后不良。

在本文的原始出版物[1]中,图7a中的标签不正确。更新的数字如下所示,现在将“ DMT1”更正为“ DNMT1”。
更新日期:2020-01-13
down
wechat
bug